| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/18/2008 | US20080227808 5-{3-[3-Bromo-5-methylsulfanyl-2-(2-pyridin-3-yl-ethoxy)-benzylamino]-propylamino}-4H-thieno[3,2-b]pyridine-7-one; anti-Clostridium difficile agents |
| 09/18/2008 | US20080227807 6-(Carbocyclylmethyl- or heterocyclylmethyl-substituted)pyrrolo[2,3-c]pyridine derivatives; use alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or mediated conditions or diseases |
| 09/18/2008 | US20080227806 prodrug is a dihydrotrigoneline CDS moiety coupled to an epoxysuccinyl peptide cysteine protease inhibitor moiety; Alzheimer's disease and vascular dementia |
| 09/18/2008 | US20080227805 Oil-in-water emulsion of buprenorphine and a surfactant; release rate is controlled by varying the oil concentration and/or pH |
| 09/18/2008 | US20080227804 Polymorphic solvates of naltrexone with ethanol, benzyl alcohol, dimethylformamide, methanol, dichloromethane, acetone and hexane; sustained release formulations |
| 09/18/2008 | US20080227803 relieving and/or preventing side effects induced by a compound having opioid receptor agonism |
| 09/18/2008 | US20080227802 Agent For Suppressing Development of Tolerance to Narcotic Analgesics |
| 09/18/2008 | US20080227801 Pharmaceutical Compositions Containing Erythrina Mulungu Derivatives, Processes for their Production and Uses Thereof |
| 09/18/2008 | US20080227800 Pyrimidylaminobenzamide Derivatives for Hypereosinophilic Syndrome |
| 09/18/2008 | US20080227799 treating or reducing the severity of hyperproliferative diseases by inhibiting metastasis |
| 09/18/2008 | US20080227798 inhibiting dipeptidyl peptidases; diabetes mellitus |
| 09/18/2008 | US20080227797 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases |
| 09/18/2008 | US20080227794 Metabotropic Glutamate-Receptor-Potentiating Isoindolones |
| 09/18/2008 | US20080227793 2-(1-Imidazomethyl)- or 2-(1-imidazooxy)-substituted, e.g., 6-chloro-2-{[2-(2-fluorophenyl)-1H-imidazol-1-yl]methyl}-1-propyl1H-benzimidazole; GABA receptor signal transduction; anxiety, antidepressants, sleep disorders, schizophrenia, attention deficit-hyperactivity disorder, memory enhancement |
| 09/18/2008 | US20080227792 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters |
| 09/18/2008 | US20080227791 treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects; N-[1-(4-fluorobenzyl)piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine |
| 09/18/2008 | US20080227790 treating an airway disorder; 4-(3-{3,4-dimethoxyphenyl}-5,5-dimethyl-6-oxo-5,6-dihydro-4H-pyridazin-1-yl)-benzoic acid |
| 09/18/2008 | US20080227789 5-(quinoxalin-2-yl)-N2-(3,4,5-trimethoxyphenyl)thiazole-2,4-diamine; useful in inhibiting the activity of the receptor protein tyrosine kinase Axl; rheumatoid arthritis, vascular disease, vascular injury, psoriasis, visual impairment due to macular degeneration, diabetic retinopathy, retinopathy |
| 09/18/2008 | US20080227788 1-Carbocyclyl- or heterocyclyl-substituted 3-substituted imidazo[1,5-a]pyrazin-8-ylamine derivatives, e.g., 1-(3-Benzyloxy-phenyl)-3-cyclobutylimidazo[1,5-a]pyrazin-8-ylamine; inhibitor of IGF-1R enzyme; treating many diseases including cancer, respiratory diseases, ulcers, and cardiovascular diseases |
| 09/18/2008 | US20080227787 4-tert-Butyl-N'-(2-(hydroxyimino)-1-phenylethylidene)benzohydrazide; treatment of inflammation |
| 09/18/2008 | US20080227786 Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor |
| 09/18/2008 | US20080227785 BEC 1 potassium channel inhibitors, used to treat dementia and learning disorders; e.g., N-(4-fluorophenyl)-N'-isopropyl-N''-phenyl-1,3,5-triazine-2,4,6-triamine hydrochloride |
| 09/18/2008 | US20080227784 5-chloro-N-(3-fluoro-4-morpholinophenyl)-2-hydroxybenzamide; prophylactic and/or therapeutic treatment of diseases caused by an activation of STAT6 and/or NF- kappa B |
| 09/18/2008 | US20080227783 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors |
| 09/18/2008 | US20080227782 Pyrimidine amide compounds as pgds inhibitors |
| 09/18/2008 | US20080227781 Imidazole compounds for the treatment of neurodegenerative disorders |
| 09/18/2008 | US20080227780 Soluble epoxide hydrolase inhibitors |
| 09/18/2008 | US20080227779 6-chloro-N-(pyrimidin-5-yl)-3-(3-(trifluoromethyl)phenylamino)benzo[d]isoxazole-7-carboxamide; autoimmune disease, allergies, mastcytosis, mast cell related tumors and various fibrotic diseases |
| 09/18/2008 | US20080227778 6-Methoxy-3-(methoxymethyl)-2-methyl-4-phenylisoquinolin-1(2H)-one; treat cardiac arrhythmias |
| 09/18/2008 | US20080227777 Pyrazolopyridine derivatives as inhibitors of beta-Adrenergic Receptor Kinase 1 |
| 09/18/2008 | US20080227776 inhibiting heme-induced lipid peroxidation; preventing isoprostane-mediated tissue damage |
| 09/18/2008 | US20080227775 Quinoline Derivatives as Antibacterial Agents |
| 09/18/2008 | US20080227774 5,5-disubstituted-indolizinone compounds |
| 09/18/2008 | US20080227773 N-[4-(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-phenyl]-benzamide; disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse |
| 09/18/2008 | US20080227772 Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands |
| 09/18/2008 | US20080227771 Delta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
| 09/18/2008 | US20080227770 Benzoxazepine Compound |
| 09/18/2008 | US20080227769 Compounds for the Treatment of Hepatitis C |
| 09/18/2008 | US20080227768 treating a bacterial infection selected from the group consisting of Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli and Pseudomonas aeruginosa |
| 09/18/2008 | US20080227767 Methods and compounds for inhibiting amyloid deposits |
| 09/18/2008 | US20080227765 Cytotoxic depsipeptides |
| 09/18/2008 | US20080227764 E.g., 3,-30-pregnanediones or 11,20-pregnanedioles; optionally in association with one or more other analgesic compounds such as opioids; does not result in overt sedation |
| 09/18/2008 | US20080227763 Administering hormone replacement therapy by applying a gel of Nomegestrol or Nomegestrol acetate to the skin; restoring genital bleeding in menopausal women |
| 09/18/2008 | US20080227762 Lupeol anti-tumor agent and uses thereof |
| 09/18/2008 | US20080227761 Ameliorating a Th1 mediated immune pathology such as multiple sclerosis by raaising the serum concentration of estrogen to 30-1000 pg/ml by administering, e.g., 17-beta-estradiol, estriol or estrone; and administering a glatiramer acetate |
| 09/18/2008 | US20080227760 Using gradient salting-out instead of conventional silica gel chromatography enables convenient performance and mass production; preventing and treating dementia, depression, and peripheral circulation disorder |
| 09/18/2008 | US20080227759 Topical composition |
| 09/18/2008 | US20080227758 Nitric Oxide Releasing Prodrugs of Diaryl-2-(5h)-Furanones as Cyclooxygenase-2 Inhibitors |
| 09/18/2008 | US20080227757 5-aminolevulinic acid, polyether polyol, lipids, dimethyl isosorbide, C2-C4-alcohol, and water; penetration-reinforcing effect for amphiphilic, zwitterionic or strongly polar pharmaceutical active ingredients; photodynamic therapy |
| 09/18/2008 | US20080227756 Administering a bisphosphonate until the bone mineral density is within a normal range, interrupting administration to enable the development of the sectional momentum of inertia, and resuming administration when the bone mineral density falls by 5-10% of the normal range |
| 09/18/2008 | US20080227755 Treatment of rheumatoid arthritis by intermittently administering a bisphosphonate; the period between administrations is 2-4 months |
| 09/18/2008 | US20080227754 Phosphoramidate linkages; retroviral or hepadnaviral therapy; tissue targeted therapy; HIV/aquired immunodeficiency syndrome; antitumor agents; improved bioavailability |
| 09/18/2008 | US20080227753 Nutritional supplements; produced by pulverizing at cryogenic temperatures to preserve the natural components of bagasse, natural color and absorbs color evenly so that it could be used as a natural foundation material for cosmetic products |
| 09/18/2008 | US20080227752 Methods to Inhibit Histone Acetyltransferase Using Glycosaminoglycans |
| 09/18/2008 | US20080227751 Method and agent for the prevention, inhibition and treatment of sepsis |
| 09/18/2008 | US20080227750 Complex of glycan and galactin accumulated on cell surfaces; therapy, prevention of autoimmune diseases |
| 09/18/2008 | US20080227749 Dyspareunia; vaginal and/or vulvar administration of formulations as a lubricant |
| 09/18/2008 | US20080227748 Medicament Made From Laminarine or Oligolaminarines For Treatment of Septicemia and Septic Shock |
| 09/18/2008 | US20080227747 Composition and methods for treating or preventing degenerative joint and cardiovascular conditions |
| 09/18/2008 | US20080227746 Using cobinamide, or a biologically active derivative or analog for therapy of sepsis, chronic liver failure, cirrhosis, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome, cirrhotic cardiomyopathy, hemodialysis-related hypotension, cardiogenic shock, ischemia-reperfusion injury |
| 09/18/2008 | US20080227745 Methods and compositions for soluble CPG15 |
| 09/18/2008 | US20080227744 Benzofuran derived hiv protease inhibitors |
| 09/18/2008 | US20080227743 Amantadine or rimantadine, and ribavirin or viramidine, and optionally a neuraminidase inhibitor such as oseltamivir, zanamivir, or peramivir |
| 09/18/2008 | US20080227742 Photocleavable oligonucleotide and uses thereof |
| 09/18/2008 | US20080227741 Zap-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (cll/sll) |
| 09/18/2008 | US20080227740 Compositions and Methods for Elimination of Unwanted Cells |
| 09/18/2008 | US20080227739 Isolated polypeptide comprising amino acid sequence encoded by polynucleotide; physiologically acceptable carriers and immunostimulants |
| 09/18/2008 | US20080227738 Compositions and methods for cell dedifferentiation and tissue regeneration |
| 09/18/2008 | US20080227737 Comprises nucleotide sequences for use as diagnostic tools in identifying allelic sequences associated with blood sugar defects |
| 09/18/2008 | US20080227736 Used to transduce heterologous genes into a cell and can be used for in vivo and ex vivo therapeutic applications, as well as for diagnostic and research tool applications |
| 09/18/2008 | US20080227735 Nucleic acid is contactd with cells not expressing receptor protein-tyrosine kinase or expressing it in a nonactivated form (CN cells), contacting first subset S1 of nucleic acids with Ci cells, contacting second subset S2 with CTe cells, amplifying nucleic acids; identifying ligands or aptamers |
| 09/18/2008 | US20080227734 Mutant Lrp5/6 Wnt-Signaling Receptors in Cancer Diagnosis, Prognosis, and Treatment |
| 09/18/2008 | US20080227733 Administering short interfering RNAs (siRNA) which modulates Fas-protein encoding gene expression for inhibiting Fas-protein regulated apoptosis in a cell |
| 09/18/2008 | US20080227732 Treatment and Control of Severe Infections Including Cystic Fibrosis |
| 09/18/2008 | US20080227731 Biphenyl inhibitors of carbonyl reductase |
| 09/18/2008 | US20080227730 9A-Carbamoyl and Thiocarbamoyl Azalides With Antimalarial Activity |
| 09/18/2008 | US20080227729 Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| 09/18/2008 | US20080227728 Therapeutic Agent for the Treatment of a Condition Associated with Peripheral Vascular Disease |
| 09/18/2008 | US20080227727 Administering topoisomerase inhibitor (such as camptothecin, irinotecan, topotecan, doxorubicin, teniposide, etoposide ) and E3 ubiquitin ligase inhibitor 2-(4-vinylpyridynyl)1,3-diacyl/thiocarbonyl indene derivative for modulating cell growth |
| 09/18/2008 | US20080227724 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents |
| 09/18/2008 | US20080227709 Gene expression in peripheral blood mononuclear cells from children with diabetes |
| 09/18/2008 | US20080227705 Apoptosis-inducing agent and method for inducing apoptosis |
| 09/18/2008 | US20080227698 oligopeptide antagonizes binding of DKK1 to LRP5 when in contact with LRP5; degenerative bone diseases |
| 09/18/2008 | US20080227695 reduced expression and/or function of Dlg (discs large) is an important factor for tumor formation; measuring the expression and/or function of Dlg |
| 09/18/2008 | US20080227690 Particles for inhalation having rapid release properties |
| 09/18/2008 | US20080227689 Autoimmune disorders; polypeptide GalNAc transferase 1 (ppGalNAcT-1) suppression; antisense RNA |
| 09/18/2008 | US20080227684 Small Molecule Inhibitors of PDZ Interactions |
| 09/18/2008 | US20080227683 Compounds Having Antitumor Activity |
| 09/18/2008 | US20080227138 Identifying sclerostin antagonist via abilty to prevent apoptosis; treating osteoporosis |
| 09/18/2008 | US20080227135 Autoimmune Conditions and NADPH Oxidase Defects |
| 09/18/2008 | US20080227127 Human NK3-Related Prostate Specific Gene-1 |
| 09/18/2008 | US20080227082 Method of identifying a mhc class i restricted t cell response |
| 09/18/2008 | US20080226759 System for treating addictions |
| 09/18/2008 | US20080226758 Formulation for improving lipoprotein profiles in mammals comprising at least one processed Morinda citrifolia product present in amount by weight of 0.1-99 percent; for reducing LDL lipoprotein levels, increasing HDL lipoprotein levels, decreasing absorption of fatty acid across intestinal epithelium |
| 09/18/2008 | US20080226757 Use of a Ginkgo Complexes for the Enhancement of Cognitive Functions and the Alleviation of Mental Fatigue |
| 09/18/2008 | US20080226756 Compositions comprising a c-glycoside compound |
| 09/18/2008 | US20080226752 For administration to African-American patients; congestive heart failure; sustained release |
| 09/18/2008 | US20080226747 Cell proliferation; anticancer agents; bioavailability |
| 09/18/2008 | US20080226745 Algal oil, triglyceride oil combined with phospholipid/protein and/or dried marine microalgae |
| 09/18/2008 | US20080226742 Non-porous microparticles comprising hydrophobic polymer and plasticizer; controlled release |